Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Pfizer's COVID Vaccine Growth Story Already Over?

TheMotleyFool

0 0

Is Pfizer's COVID Vaccine Growth Story Already Over?

No matter how you look at it, Pfizer (NYSE: PFE) has had a remarkable year in 2020. The big drugmaker made a critical decision early on to team up with German biotech BioNTech (NASDAQ: BNTX) on developing a COVID-19 vaccine. That decision has paid off, with Pfizer and BioNTech becoming the first coronavirus-vaccine makers to win emergency use authorization (EUA) in the U.S.

Pfizer stock generated double-digit percentage gains over the last month as investors' enthusiasm about its coronavirus vaccine rose. However, those gains have now all but evaporated. Is Pfizer's COVID vaccine growth story already over?

Image source: Getty Images.

Source Fool.com

Like: 0

PFE

Share